Selected research
Industry Research
RNA Vaccines Industry Research Report 2026
Market perspective
The global RNA Vaccines market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for RNA Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for RNA Vaccines is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for RNA Vaccines is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of RNA Vaccines include Translate Bio, Tiba Biotechnology, Sangamo Therapeutics, Moderna Therapeutics, In-Cell-Art, Ethris, eTheRNA, CureVac and BioNTech, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global RNA Vaccines market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
RNA Vaccines Market by Company
Translate Bio
Tiba Biotechnology
Sangamo Therapeutics
Moderna Therapeutics
In-Cell-Art
Ethris
eTheRNA
CureVac
BioNTech
Argos Therapeutics
RNA Vaccines Segment by Type
Individualized Cancer Treatment MRNA Vaccine
Infection Prevention MRNA Vaccine
Infectious Disease Treatment MRNA Vaccine
RNA Vaccines Segment by Application
Infectious Disease
Cancer
Other
RNA Vaccines Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global RNA Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of RNA Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of RNA Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of RNA Vaccines manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of RNA Vaccines by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of RNA Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Individualized Cancer Treatment MRNA Vaccine
- Infection Prevention MRNA Vaccine
- Infectious Disease Treatment MRNA Vaccine
Applications
- Infectious Disease
- Cancer
- Other
Companies covered
- Translate Bio
- Tiba Biotechnology
- Sangamo Therapeutics
- Moderna Therapeutics
- In-Cell-Art
- Ethris
- eTheRNA
- CureVac
- BioNTech
- Argos Therapeutics
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global RNA Vaccines Market Size (2021-2032)
- 2.2.2 Global RNA Vaccines Sales (2021-2032)
- 2.2.3 Global RNA Vaccines Market Average Price (2021-2032)
- 2.3 RNA Vaccines by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Individualized Cancer Treatment MRNA Vaccine
- 2.3.3 Infection Prevention MRNA Vaccine
- 2.3.4 Infectious Disease Treatment MRNA Vaccine
- 2.4 RNA Vaccines by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Infectious Disease
- 2.4.3 Cancer
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global RNA Vaccines Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global RNA Vaccines Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global RNA Vaccines Revenue of Manufacturers (2021-2026)
- 3.4 Global RNA Vaccines Average Price by Manufacturers (2021-2026)
- 3.5 Global RNA Vaccines Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of RNA Vaccines, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of RNA Vaccines, Product Type & Application
- 3.8 Global Manufacturers of RNA Vaccines, Established Date
- 3.9 Global RNA Vaccines Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Translate Bio
- 4.1.1 Translate Bio Company Information
- 4.1.2 Translate Bio Business Overview
- 4.1.3 Translate Bio RNA Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Translate Bio RNA Vaccines Product Portfolio
- 4.1.5 Translate Bio Recent Developments
- 4.2 Tiba Biotechnology
- 4.2.1 Tiba Biotechnology Company Information
- 4.2.2 Tiba Biotechnology Business Overview
- 4.2.3 Tiba Biotechnology RNA Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Tiba Biotechnology RNA Vaccines Product Portfolio
- 4.2.5 Tiba Biotechnology Recent Developments
- 4.3 Sangamo Therapeutics
- 4.3.1 Sangamo Therapeutics Company Information
- 4.3.2 Sangamo Therapeutics Business Overview
- 4.3.3 Sangamo Therapeutics RNA Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Sangamo Therapeutics RNA Vaccines Product Portfolio
- 4.3.5 Sangamo Therapeutics Recent Developments
- 4.4 Moderna Therapeutics
- 4.4.1 Moderna Therapeutics Company Information
- 4.4.2 Moderna Therapeutics Business Overview
- 4.4.3 Moderna Therapeutics RNA Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Moderna Therapeutics RNA Vaccines Product Portfolio
- 4.4.5 Moderna Therapeutics Recent Developments
- 4.5 In-Cell-Art
- 4.5.1 In-Cell-Art Company Information
- 4.5.2 In-Cell-Art Business Overview
- 4.5.3 In-Cell-Art RNA Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 In-Cell-Art RNA Vaccines Product Portfolio
- 4.5.5 In-Cell-Art Recent Developments
- 4.6 Ethris
- 4.6.1 Ethris Company Information
- 4.6.2 Ethris Business Overview
- 4.6.3 Ethris RNA Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Ethris RNA Vaccines Product Portfolio
- 4.6.5 Ethris Recent Developments
- 4.7 eTheRNA
- 4.7.1 eTheRNA Company Information
- 4.7.2 eTheRNA Business Overview
- 4.7.3 eTheRNA RNA Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 eTheRNA RNA Vaccines Product Portfolio
- 4.7.5 eTheRNA Recent Developments
- 4.8 CureVac
- 4.8.1 CureVac Company Information
- 4.8.2 CureVac Business Overview
- 4.8.3 CureVac RNA Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 CureVac RNA Vaccines Product Portfolio
- 4.8.5 CureVac Recent Developments
- 4.9 BioNTech
- 4.9.1 BioNTech Company Information
- 4.9.2 BioNTech Business Overview
- 4.9.3 BioNTech RNA Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 BioNTech RNA Vaccines Product Portfolio
- 4.9.5 BioNTech Recent Developments
- 4.10 Argos Therapeutics
- 4.10.1 Argos Therapeutics Company Information
- 4.10.2 Argos Therapeutics Business Overview
- 4.10.3 Argos Therapeutics RNA Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Argos Therapeutics RNA Vaccines Product Portfolio
- 4.10.5 Argos Therapeutics Recent Developments
5 Global RNA Vaccines Market Scenario by Region
- 5.1 Global RNA Vaccines Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global RNA Vaccines Sales by Region: 2021-2032
- 5.2.1 Global RNA Vaccines Sales by Region: 2021-2026
- 5.2.2 Global RNA Vaccines Sales by Region: 2027-2032
- 5.3 Global RNA Vaccines Revenue by Region: 2021-2032
- 5.3.1 Global RNA Vaccines Revenue by Region: 2021-2026
- 5.3.2 Global RNA Vaccines Revenue by Region: 2027-2032
- 5.4 North America RNA Vaccines Market Facts & Figures by Country
- 5.4.1 North America RNA Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America RNA Vaccines Sales by Country (2021-2032)
- 5.4.3 North America RNA Vaccines Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe RNA Vaccines Market Facts & Figures by Country
- 5.5.1 Europe RNA Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe RNA Vaccines Sales by Country (2021-2032)
- 5.5.3 Europe RNA Vaccines Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific RNA Vaccines Market Facts & Figures by Country
- 5.6.1 Asia Pacific RNA Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific RNA Vaccines Sales by Country (2021-2032)
- 5.6.3 Asia Pacific RNA Vaccines Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America RNA Vaccines Market Facts & Figures by Country
- 5.7.1 South America RNA Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America RNA Vaccines Sales by Country (2021-2032)
- 5.7.3 South America RNA Vaccines Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa RNA Vaccines Market Facts & Figures by Country
- 5.8.1 Middle East and Africa RNA Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa RNA Vaccines Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa RNA Vaccines Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global RNA Vaccines Sales by Type (2021-2032)
- 6.1.1 Global RNA Vaccines Sales by Type (2021-2032) & (k units)
- 6.1.2 Global RNA Vaccines Sales Market Share by Type (2021-2032)
- 6.2 Global RNA Vaccines Revenue by Type (2021-2032)
- 6.2.1 Global RNA Vaccines Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global RNA Vaccines Revenue Market Share by Type (2021-2032)
- 6.3 Global RNA Vaccines Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global RNA Vaccines Sales by Application (2021-2032)
- 7.1.1 Global RNA Vaccines Sales by Application (2021-2032) & (k units)
- 7.1.2 Global RNA Vaccines Sales Market Share by Application (2021-2032)
- 7.2 Global RNA Vaccines Revenue by Application (2021-2032)
- 7.2.1 Global RNA Vaccines Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global RNA Vaccines Revenue Market Share by Application (2021-2032)
- 7.3 Global RNA Vaccines Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 RNA Vaccines Value Chain Analysis
- 8.1.1 RNA Vaccines Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 RNA Vaccines Production Mode & Process
- 8.2 RNA Vaccines Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 RNA Vaccines Distributors
- 8.2.3 RNA Vaccines Customers
9 Global RNA Vaccines Analyzing Market Dynamics
- 9.1 RNA Vaccines Industry Trends
- 9.2 RNA Vaccines Industry Drivers
- 9.3 RNA Vaccines Industry Opportunities and Challenges
- 9.4 RNA Vaccines Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst